Human clinical trials using FLT3L in mesothelioma and some carcinomas have reported limited effect as a single agent.48 49 However, preclinical studies in several mouse tumor models suggest that FLT3L can be effective, particularly when used in combination with other agents. Here, FLT3LG is linked to mesothelioma.